Compare Direxion Daily CSI China Internet Bull 2X Shares (CWEB) vs Davita Inc (DVA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion Daily CSI China Internet Bull 2X Shares vs Davita Inc — how do they compare? Direxion Daily CSI China Internet Bull 2X Shares trades at $18.69 (market cap $173.62M), while Davita Inc trades at $179.56 (market cap $11.29B). The key difference: Davita Inc is far larger — about 65× Direxion Daily CSI China Internet Bull 2X Shares's market cap, and Davita Inc is trading nearer its 52-week high, Direxion Daily CSI China Internet Bull 2X Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Direxion Daily CSI China Internet Bull 2X Shares for 24 Days and Davita Inc for 113 Days on average.
| CWEB | DVA | |
|---|---|---|
Market Cap | $173.62M | $11.29B |
Volume | 551,726 | 582,204 |
Sector | Leveraged / Inverse | Health |
52-Week High | $55.62 | $240.96 |
52-Week Low | $17.39 | $103.87 |
Typical Hold Time | 24 Days | 113 Days |
Enterprise Value | — | $24.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CWEB is trading at $18.02, down 1.85% on the day, with technical indicators showing a bearish trend across moving averages. The stock faces selling pressure with all 13 moving average signals bearish and key resistance levels clustered around $18. Recent news highlights China's AI ambitions and potential growth in China tech stocks as catalysts.
The outlook remains cautious due to technical weakness, though exposure to China's growing AI sector offers long-term potential. Key risks include China market volatility and competitive pressures. Investors should monitor earnings reports for fundamental validation of growth prospects.
DaVita (DVA) trades at $176.78, down 2.01% today, with a bearish technical signal and neutral oscillators. The company shows strong earnings beats in recent quarters with Q2 2026 EPS of $4.02 beating expectations of $3.88. Revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026, though net margins have fluctuated. Recent partnership expansion with Humana for value-based kidney care represents significant business development.
DVA presents a mixed outlook with 43% analyst buy ratings and a $235.67 price target suggesting 33% upside. However, high debt levels (65.55% debt-to-asset ratio) and regulatory risks in healthcare weigh on fundamentals. The stock's current valuation at P/E 15 and P/S 0.88 appears reasonable relative to earnings growth potential, making it attractive for value investors despite near-term bearish technicals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Direxion Daily CSI China Internet Bull 2X Shares
CWEB is a leveraged ETF that seeks to provide two times (2x) the daily performance of the CSI China Internet Index. It offers magnified exposure to top Chinese internet companies listed on US and Hong Kong exchanges.
Read more on CWEB →About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →
